Drug
Orvepitant
Status:
Phase 2
Condition:
Chronic Cough
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Orvepitant is a neurokinin-1 receptor antagonist.
Study Purpose
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.